Nanomedicine in cancer stem cell therapy: from fringe to forefront
- 252 Downloads
Nanomedicine is the spin-off of modern medicine and nanotechnology and aims to prevent and treat diseases using nanoscale materials such as biocompatible nanoparticles and nanorobots. Targeted cellular and tissue-specific clinical applications with maximal therapeutic effects and insignificant side effects could be achieved by the pursuit of nanotechnology in medicine and healthcare regimen. The majority of conventional cancer therapies eliminate the cells of the tumor but not the cancer stem cells (CSCs). Conversely, the use of nanotechnology in CSC-based therapies is an emerging field of biomedical sciences. This article summarizes the recent trends and application of nanomedicine especially in CSC therapy along with its limitations.
KeywordsNanomedicine Nanomaterials Nanodevice Cancer stem cells (CSCs) Drug delivery
This work is supported by a DST (SERB/LS-310/2013) and UPCST (CST/YSS/D-2873) grant.
Compliance with ethical standards
Disclosure of potential conflicts of interest
The author(s) declare no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
- Astruc D (1996) Research avenues on dendrimers towards molecular biology: from biomimetism to medicinal engineering. C R Acad Sci 322:757–766Google Scholar
- Canter RJ, Grossenbacher SK, Ames E et al (2016) Immune targeting of cancer stem cells in gastrointestinal oncology. J Gastrointest Oncol 7(Suppl 1):S1–S10. https://doi.org/10.3978/j.issn.2078-6891.2015.066
- De Jong W, Borm P (2008) Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 3:133–149Google Scholar
- Epeius Biotech, http://www.epeiusbiotech.com/oncology- RexinG-factsheet.asp
- European Science Foundation (2005) Forward Look Nanomedicine: An EMRC Consensus Opinion. Available online: http://www.esf.org (accessed on 21 December 2015)
- Food and Drug Administration (2016) FDA approves new, targeted treatment for bladder cancer: Tecentriq is the first PD-L1 inhibitor approved by the FDA. FDA News ReleaseGoogle Scholar
- Gabizon A, Catane R, Uziely B et al (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 4:987–992Google Scholar
- Galen US (2011) DaunoXome: daunorubicin citrate liposome injection. http://daunoxome.com/downloads/DaunoXome%20PI.pdf
- Hallett RM, Kondratyev MK, Giacomelli AO et al (2012) Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer. PLoS One 7:e33976. https://doi.org/10.1371/journal.pone.0033976 CrossRefPubMedPubMedCentralGoogle Scholar
- Jain KK (2008) The handbook of nanomedicine. Humana Press Totowa NJ USAGoogle Scholar
- Sell S (2009) Regulatory networks in stem cells. Stem Cell Biology and Regenerative Medicine:495–503Google Scholar
- Singh OP, Nehru RM (2008) Nanotechnology and cancer treatment. Asian J Exp Sci 22:45–50Google Scholar
- Sopherion therapeutics. Myocet: doxorubicin hydrochloride (liposome) for injection. http://www.sopherion.com/pdf/PIEnglishv0-2.pdf (2001)
- Sun R, Liu Y, Li S et al (2015) Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. Biomaterials 37:405–414. https://doi.org/10.1016/j.biomaterials.2014.10.018 CrossRefPubMedGoogle Scholar
- Trivedi N, Patel N, Upadhyay UM et al (2012) Gold nanoparticulate drug delivery system: a review. Pharmacie Globale International Journal of Comphrehesive Pharmacy 6:1–5Google Scholar
- Trouet A, Masquelier M, Baurain R et al (1982) A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc Natl Acad Sci U S A 79:626–629CrossRefGoogle Scholar